Cerner Corporation (NASDAQ: CERN) and Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.

Analyst Recommendations

This is a summary of recent ratings and target prices for Cerner Corporation and Invivo Therapeutics Holdings Corp, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cerner Corporation 0 12 7 1 2.45
Invivo Therapeutics Holdings Corp 0 1 0 0 2.00

Cerner Corporation presently has a consensus price target of $67.47, indicating a potential downside of 5.66%. Invivo Therapeutics Holdings Corp has a consensus price target of $6.00, indicating a potential upside of 293.44%. Given Invivo Therapeutics Holdings Corp’s higher possible upside, analysts plainly believe Invivo Therapeutics Holdings Corp is more favorable than Cerner Corporation.

Profitability

This table compares Cerner Corporation and Invivo Therapeutics Holdings Corp’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cerner Corporation 13.47% 18.18% 12.93%
Invivo Therapeutics Holdings Corp N/A -118.45% -96.82%

Insider & Institutional Ownership

78.9% of Cerner Corporation shares are held by institutional investors. 13.2% of Cerner Corporation shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Cerner Corporation and Invivo Therapeutics Holdings Corp’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cerner Corporation $4.90 billion 4.84 $1.37 billion $1.98 36.12
Invivo Therapeutics Holdings Corp N/A N/A -$25.77 million N/A N/A

Cerner Corporation has higher revenue and earnings than Invivo Therapeutics Holdings Corp.

Summary

Cerner Corporation beats Invivo Therapeutics Holdings Corp on 10 of the 11 factors compared between the two stocks.

About Cerner Corporation

Cerner Corporation (Cerner) is a supplier of healthcare information technology (HCIT). The Company offers a range of intelligent solutions and services that support the clinical, financial and operational needs of organizations of all sizes. The Company’s segments include Domestic and Global. The Domestic segment includes revenue contributions and expenditures associated with business activity in the United States. The Global segment includes revenue contributions and expenditures linked to business activity in Aruba, Australia, Austria, the Bahamas, Belgium, Bermuda, Brazil, Canada, Cayman Islands, Chile, Denmark, Egypt, England, Finland, France, Germany, Guam, India, Ireland, Kuwait, Luxembourg, Malaysia, Mexico, the Netherlands, Norway, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovakia, Spain, Sweden, Switzerland and the United Arab Emirates. The Company’s solutions are offered on the unified Cerner Millennium architecture and on the HealtheIntent cloud-based platform.

About Invivo Therapeutics Holdings Corp

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Receive News & Ratings for Cerner Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerner Corporation and related companies with MarketBeat.com's FREE daily email newsletter.